Future study of this replicated and validated risk variant, i.e., HLA-DRB1 position 11, is needed to generate new insights and better understanding of the implication of the risk variant for the pathophysiology of ACPA-positive RA. This evidence concerns the gene HLA-DRB1 and rheumatoid arthritis.